ABSTRACT
Cutaneous melanoma has continued to increase at a skyrocketing pace. In developing agents for the chemoprevention of melanoma, scientific rationale must be consistent with known pathways implicated in the pathogenesis of cutaneous melanoma. The role of RAS signaling in melanoma is likely multifaceted. In developing agents for the chemoprevention of melanoma, scientific rationale must be consistent with known pathways implicated in the pathogenesis of cutaneous melanoma. A relevant consideration for melanoma chemoprevention is the administration of the agent itself. Among the potential chemo-prevention agents for melanoma that satisfy the scientific rationale, statins have known and acceptable toxicities. Statins appear to satisfy the majority of the prerequisites for a valid melanoma chemoprevention strategy. A chemoprevention strategy that would target early molecular events in melanoma could potentially result in profound improvements in the incidence and morbidity and mortality from melanoma.
